Publication

Cancer Donor Preferences for Disposition of Their Biospecimens After Biobank Closure

Downloadable Content

Persistent URL
Last modified
  • 05/15/2025
Type of Material
Authors
    Samuel C. Allen, Emory UniversityMargie D. Dixon, Emory UniversityJeffrey Switchenko, Emory UniversityRebecca Pentz, Emory University
Language
  • English
Date
  • 2017-12-01
Publisher
  • Wiley: 12 months
Publication Version
Copyright Statement
  • © 2017 American Cancer Society
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0008-543X
Volume
  • 123
Issue
  • 23
Start Page
  • 4648
End Page
  • 4652
Grant/Funding Information
  • Funding sources: Research reported in this publication was supported in part by an NIH funded R01 HG008348, PI Christopher Simon,”Interactive multimedia consent for biobanking” and by the Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Abstract
  • BACKGROUND: Biobank funding is unstable and biobank administrators are concerned about loss of funding and subsequent biobank closure. Nevertheless, only a minority of biobanks have policies regarding the distribution or destruction of tissue if the biobank were to close. To the authors' knowledge, the current study is the first to report on the preferences of oncology biospecimen donors regarding the handling of their biospecimens in the event of biobank closure. METHODS: A total of 98 biospecimen donors who were diagnosed with cancer at the Georgia Cancer Center for Excellence at Grady Memorial Hospital or the Winship Cancer Institute were interviewed concerning their preferences for the handling of their biospecimens in the event of biobank closure. RESULTS: The majority of biospecimen donors who expressed a preference (62 of 83 donors; 75%) wanted their biological materials transferred to another biobank, specifically an academic bank or a national bank. The most unacceptable options for the handling of tissue were transfer to a for-profit/pharmaceutical biobank (39 of 98 donors; 40%) or a biobank based outside of the United States (31 of 98 donors; 32%). Nonwhite participants were more likely to view the transfer of their tissue to a for-profit/pharmaceutical tissue bank, international tissue bank, or a national tissue bank as unacceptable compared with white participants. CONCLUSIONS: According to these biospecimen donors, the most acceptable options for the handling of biospecimens after biobank closure were transfer to an academic or national bank. The most objectionable options were transfer to a for-profit/pharmaceutical biobank or a biobank based outside of the United States. These findings can be used as the basis for educational interventions directed at the public and can inform the policies of biobanks that serve oncology research. Cancer 2017;123:4648-4652. © 2017 American Cancer Society.
Author Notes
  • Address correspondence to: Rebecca D. Pentz, PhD, Professor of Research Ethics, Winship Cancer Institute, Emory School of Medicine, 1365 Clifton Road, NE, Atlanta, GA 30322, Phone: 404 778 5694, FAX: 404 778 3366, rpentz@emory.edu.
Keywords
Research Categories
  • Health Sciences, Oncology

Tools

Relations

In Collection:

Items